Treatment Resistance Risk in Patients with Newly Diagnosed Multiple Myeloma Is Associated with Blood Hypercoagulability: The ROADMAP-MM Study

Treatment Resistance Risk in Patients with Newly Diagnosed Multiple Myeloma Is Associated with Blood Hypercoagulability: The ROADMAP-MM Study

Biomarkers of hypercoagulability are potential candidates for the evaluation of risk for primary treatment resistance in patients with newly diagnosed multiple myeloma (NDMM). This study aimed to identify the most clinically relevant biomarkers for the evaluation of treatment-resistance risk. NDMM p...

Full description

Bibliographic Details
Main Authors: Grigorios T. Gerotziafas, Despina Fotiou, Theodoros N. Sergentanis, Loula Papageorgiou, Jawed Fareed, Anna Falanga, Michèle Sabbah, Laurent Garderet, Evangelos Terpos, Ismail Elalamy, Patrick Van Dreden, Meletios A. Dimopoulos
Format: Article
Language:English
Published: MDPI AG 2022-02-01
Series:Hemato
Subjects:
D-Dimer
hypercoagulability
multiple myeloma
thrombin generation
treatment resistance
Online Access:https://www.mdpi.com/2673-6357/3/1/16

Internet

https://www.mdpi.com/2673-6357/3/1/16

Similar Items